Relationship between exhaled markers and airway pathology in smokers with and without airflow obstruction

Relationship between exhaled markers and airway pathology in smokers with and without airflow obstruction - Biomarkers in smokers with and without airflow obstruction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34947

Enrollment

Registered

2010-04-20

Start date

2010-10-12

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic bronchitis emphysema

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Male or female subject, age > 40 years, current or ex-smokers - Plannend lung resection for primary lung cancer of any size. - COPD: irreversible airflow limitation (postbronchodilator FEV1/FVC 70% -Written informed consent.

Exclusion criteria

Exclusion criteria: -Patients with a history of asthma or other active lung disease. -Lung resection for other reasons than lung cancer (e.g. infective diseases like bronchiectasis).

Design outcomes

Primary

Measure	Time frame
To demonstrate that the change in slope of the sbN2-test (phase III/IV) is correlated to an influx of inflammatory cells in the small airways (histology, morphology, immunopathology) and to inflammatory markers in exhaled breath in patients with normal and abnormal small airways function.	—

Secondary

Measure	Time frame
To demonstrate that the presence of lung cancer per se is a condition leading to a change in the breath pattern. Exhaled breath patterns will be assessed by the eNose and the differential mobility spectrometry before and after lung cancer surgery. To assess whether there is a difference in expression of macrophage Mf1 and Mf2 markers, and in mast cell subsets (chymase/tryptase positive vs. tryptase positive) in small and large airways from patients with COPD at lung tissue level. Furthermore we are interested whether there is a relationship between the expression of the 1,25(OH)2D3 degrading enzyme CYP24A1 and antimicrobial peptides in small and large airways in COPD patients and whether there is a correlation with local inflammation and lung function.	—

Measure

Time frame

To demonstrate that the presence of lung cancer per se is a condition leading to a change in the breath pattern. Exhaled breath patterns will be assessed by the eNose and the differential mobility spectrometry before and after lung cancer surgery. To assess whether there is a difference in expression of macrophage Mf1 and Mf2 markers, and in mast cell subsets (chymase/tryptase positive vs. tryptase positive) in small and large airways from patients with COPD at lung tissue level. Furthermore we are interested whether there is a relationship between the expression of the 1,25(OH)2D3 degrading enzyme CYP24A1 and antimicrobial peptides in small and large airways in COPD patients and whether there is a correlation with local inflammation and lung function.

—

Countries

Netherlands

Outcome results